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Abstract
Background: The vascular type of Ehlers–Danlos syndrome is an autosomal dominant connective tissue disorder
caused by a mutation in the COL3A1 gene encoding pro-alpha1 chain of type III collagen. The vascular type of
Ehlers–Danlos syndrome causes severe fragility of connective tissues with arterial and intestinal ruptures and
complications in surgical and radiological treatments.
Case presentation: We present a case of a 38-year-old Italian woman who was diagnosed as having the vascular
type of Ehlers–Danlos syndrome. Genetic testing, conducted by Target Enrichment approach (Agilent Technologies),
identified a new mutation c.1493G>A, p.G498D in exon 21 of COL3A1 gene (heterozygous state). This mutation
disrupts the normal glycine-X-Y repetitions of type III procollagen by converting glycine to aspartic acid.
Conclusions: We report a new genetic mutation associated with the vascular type of Ehlers–Danlos syndrome. We
also describe clinical and genetic findings that are important to understand the genotype/phenotype correlation in
patients with the vascular type of Ehlers–Danlos syndrome.
Keywords: Ehlers–Danlos syndrome vascular type, COL3A1 gene, Next-generation sequencing, HaloPlex Target
Enrichment, Sanger sequencing
Background
Ehlers–Danlos syndrome (EDS) is a group of heteroge-
neous connective tissue disorders. It is characterized by
abnormalities of the molecules that configure the extracel-
lular matrix, such as collagen or its modifying enzymes
[1]. The clinical characteristics of EDS are: hyperextensi-
bility of the skin, hypermobility of the large joints, and
easy bruising. On the basis of clinical experience and gen-
etic findings, EDS is divided in six subtypes, (Villefranche
classification 1997): (1) classic, which is the most frequent
form; (2) hypermobility; (3) kyphoscoliosis; (4) arthrocha-
lasia; (5) dermatosparaxis; and (6) vascular, which is the
most dramatic form [2]. Genetic and clinical findings of
EDS subtypes point out the genetic heterogeneity of EDS
syndrome. Therefore, diagnosing the correct EDS type has
important implications for genetic counseling and man-
agement. Any subtype of EDS is supported by specific
biochemical and molecular investigations [1].
Vascular type of EDS (vEDS), also known as EDS type
IV (NIM#130050), is a rare inherited autosomal dominant
disorder with an estimated prevalence of 1 in 150,000.
There are four main characteristics of vascular EDS: (1)
rupture of blood vessels or internal organs such as the
uterus and intestines, (2) an unusual facial appearance, (3)
easy bruising, and (4) translucent skin with visible veins
[3]. An important clinical event in vEDS is that the sys-
temic arteries, which are rich in type III collagen, may
undergo dissection, aneurysm, or rupture. These dramatic
events may also occur spontaneously [4].
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The genetic cause of vEDS is the presence of muta-
tions in the collagen type III, alpha 1 gene (COL3A1),
resulting in qualitative and/or quantitative abnormal-
ities of mature type III collagen protein. Type III pro-
collagen protein consists of 343 glycine (Gly)-X-Y
repetitions (X and Y, any other amino acids) in each of
the three amino acid chains. Mature type III collagen
fiber comprises 3 alpha-1(III) chains. More than 200
mutations of the COL3A1 gene have been described so
far (www.le.ac.uk/ge/collagen), all of which lead to syn-
thesis of an abnormal type III collagen protein (Fig. 1).
In this case report we describe a novel COL3A1 point
mutation (c.1493G>A, p.G498D) in a 38-year-old Italian
woman. The diagnosis of vEDS was achieved at the
Regional Center of Ehlers-Danlos syndrome (Ospedale
Maggiore Policlinico, Milan, Italy); in addition to typical
clinical characteristics of vEDS she referred an intestinal
ischemic perforation of the sigmoid-rectum. The novel
COL3A1 mutation c.1493G>A, p.G498D that we describe
here for the first time, is associated with profound change
in the protein structure, causing vEDS.
Case presentation
A 38-year-old Italian woman presented to our Regional
Center of Ehlers-Danlos Syndrome, Ospedale Maggiore
Policlinico, Milan, Italy, with a previous diagnosis of
vEDS. She referred an intestinal ischemic perforation
of the sigmoid-rectum with stercoral peritonitis treated
with resection of her sigmoid-rectum and creation of a
stoma. She did not have familial history of vEDS. When
she was 26-years old and had not yet had a clinical
diagnosis of EDS she underwent an orthopedic inter-
vention for alignment of the internal arch plus tarsal
sinus arthrodesis of both feet.
We applied next-generation sequencing (NGS) to in-
vestigate genomic regions of interest through target
enrichment; it was performed by means of a HaloPlex
Target Enrichment kit (Agilent Technologies). Probes
for all coding exons, including intron–exon boundaries,
were designed by the HaloPlex SureDesign website
(www.genomics.agilent.com). The nine genes included in
the design were selected on the basis of their clinical
characteristics (www.le.ac.uk/ge/collagen; Table 1). The
total region size was 100.336 kbp for an actual analyzed
target of 99.718 kbp bases. Enrichment was performed
according to the supplier’s protocol (version D.6, August
2014). A total of 225 ng DNA was digested in eight dif-
ferent restriction reactions during 30 minutes at 37 °C.
The eight digestion reactions were combined into a sin-
gle hybridization mix containing target-specific probes.
Hybridization reaction was performed in a 3-hour reaction
at 54 °C. Probes were labeled with biotin and designed to
hybridize to both ends of the digested fragments, therefore
generating circular fragments containing one nick. Then,
the DNA probe hybrids were captured with streptavidin
beads to eliminate linear non-target DNA fragments. In a
second ligation reaction, the remaining nick was closed
to complete circularization. The captured DNA was
eluted from the beads and amplified by polymerase
chain reaction (PCR) reaction, followed by a final puri-
fication reaction with AMPure XP beads (Beckman
Coulter, Fullerton, CA, USA).
Finally, the concentration of each library was measured
by TapeStation software and were diluted at 4nmol with
TE. The final pool was obtained by mixing different gen-
omic libraries and the ideal final concentration was 8 pM
(ideal concentration for cluster density approximately
900/1000 K/mm2). Captured genomic libraries were se-
quenced to generate 2×150 bp paired end reads using the
Illumina MiSeq.
To understand the generated FASTQ files (a file that
stores a biological sequence and its quality score), aa) b)
Fig. 1 Schematic representation of mature type III collagen fibers in:
a wild type and b mutant case respectively. If there are mutations in
one COL3A1 allele the dominant negative effect is a dramatic
reduction in qualitative and quantitative production of COL3A1
protein. gDNA genomic DNA, mRNA messenger RNA, mut mutant
Table 1 List of genes included in the HaloPlex Target Enrichment
panel (next-generation gene panel)
Gene OMIM Phenotype Chromosome
ADAMTS2 604539 EDS type VIIC chr5q.35.3
B4GALT7 604327 EDS progeroid type 1 chr5q35.3
CHST14 608429 EDS muscolocontractural type 1 chr15q15.1
COL3A1 120180 EDS type IV chr2q32.2
COL5A1 120215 EDS classic type chr9q34.3
COL5A2 120190 EDS classic type chr2q32.2
PLOD1 153454 EDS type VI chr1p36.22
PLOD3 603066 Lysyl hydroxylase 3 deficiency chr7q22.1
TNXB 600985 EDS due to tenascin X deficiency chr6p21.33
EDS Ehlers–Danlos syndrome, OMIM Online Mendelian Inheritance in Man
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workflow was set up by Galaxy software (https://usegalaxy.
org/) [5]. FASTQ files were evaluated by quality and they
were trimmed, aligned, and mapped to the human refer-
ence genome (GRCh38/hg38) using Burrows-Wheeler
Aligner [6, 7]. Alignments including sorting, merging,
indexing, and generating alignments in a per-position for-
mat were manipulated by SAM tools [8, 9] to generate a
BAM (binary format for storing sequence) file. Local re-
alignment, base quality recalibration, and variant calling
were performed using Genome Analysis Toolkit (GATK)
version 2.0 (Broad Institute, Cambridge, MA, USA) [10]
applying these quality parameters: coverage>20, base qual-
ity score>30, and mapping quality>20. Variants that did
not pass these quality values were removed.
Finally, the Variant Calling Files (VCF) were filtered
through different parameters such as genotype quality
filters, gene feature filters (missense, splicing, frame shift),
and functional impact filters using KGGSeq software [11].
The variants found with NGS target enrichment method
were confirmed by Sanger method using BigDye Termin-
ator Cycle Sequencing Kit (Applied Biosystems, Life
Technologies) followed by capillary electrophoresis on an
Applied Biosystems 3130xl (Applied Biosystems). Electro-
pherograms were analyzed by Sequencher software v5.1.
To investigate the pathogenetic properties of a missense
variant, different types of software were used: SIFT,
PROVEAN, PolyPhen-2, Mutation Taster, Grantham
distance, and Align GVGD; these types of software are
based on sequence homology, the physiochemical similar-
ity between the alternate amino acids, effect of an amino
acid substitution on the structure and function of a
protein, and conservation level of the amino acid resi-
due among species [12–15].
Resequencing by target enrichment approach (HaloPlex
technique) conducted using our custom panel (Table 1)
showed the presence of an undescribed mutation in exon
21 of COL3A1 gene at position 1493 leading to a nucleo-
tide replacement (c.1493G>A, p.G498D) (www.le.ac.uk/ge/
collagen/). It was confirmed by Sanger method on a sec-
ond DNA extraction. Moreover, a complementary DNA
(cDNA) analysis extracted from fibroblasts culture was not
feasible due to the extreme fragility of the clinical state of
our patient. 343 Gly-X-Y repetitions (X and Y, any other
amino acids)
Figure 2 shows that c.1493G>A, p.G498D was a mis-
sense variant causing a substitution from Gly, a neutral
amino acid, to aspartic acid, a polar amino acid, and it
was located on the triple-helical region of the structure
of the protein. Type III procollagen protein consists of
343 repetitions of Gly-X-Y (X and Y, any other amino
acids) in each of three amino acids, which is a feature of
collagen specificity. The mature type III collagen fibers
Fig. 2 a Schematic structure of COL3A1 gene (NG_007404.1) is located on chr2q31 and composed of 51 exons. b COL3A1 DNA sequence in an
unaffected individual and in a patient with vascular type of Ehlers–Danlos syndrome. Each nucleotide is indicated with a different color: A green,
C blue, G black, T red
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consist of 3 alpha-1(III) chains. The mutation in one
allele of COL3A1 resulted in qualitative or quantitative
abnormalities of mature type III collagen protein (Fig. 2)
[16]. To evaluate the functional effect of mutation, we
performed an in silico analysis using SIFT, PROVEAN,
PolyPhen-2, and Align GVGD; all of these tools pre-
dicted that this change is causing the disease [12–15].
PolyPhen-2 software prediction, based on two datasets
(Human Diversity and Human Variation), indicated that
c.1493G>A, p.G498D is probably damaging for the
structure of the protein with a score of 1.000 (sensitivity
0.00; specificity 1.00; Fig. 3). In particular, the Gly at
1493 position was extremely conserved through different
species. SIFT and PROVEAN software, which evaluate
whether an amino acid substitution has an impact on
the biological function of the protein, confirmed the
pathogenicity of the missense variant. Align GVGD, rely-
ing on the biophysical characteristics of the amino acids,
predicted that this variant was not tolerated C65 (GV
0.00; GD 93.77; Fig. 3). It was impossible to analyze the
effect of the mutation on the three-dimensional protein
structure because at present there is no sequence hom-
ology reference to build the structure.
Discussion
In the current case report we described a case of a 38-
year-old Italian woman with typical symptoms of vEDS.
She referred an ischemic perforation of her sigmoid-
rectum with stercoral peritonitis treated with resection
of sigmoid-rectum and creation of a stoma. The stoma
was not closed to avoid surgical complications. Her in-
testinal problems worsened her clinical state. A physical
examination revealed that her skin was slightly smooth
and translucent with visible veins. Genetic analysis did
not confirm any familial history.
Using a target NGS approach (HaloPlex protocol), a
pathogenetic mutation c.1493G>A, p.G498D was discov-
ered in the COL3A1 gene (www.le.ac.uk/ge/collagen/).
Up to now, more than 200 mutations in the COL3A1
gene have been identified [17], all of which lead to the
synthesis of an abnormal type III procollagen protein
(Fig. 1). Approximately, two thirds of the mutations are
single nucleotide substitutions that result in change for
Gly residues in the triple helical domain of the proα1(III)
chain. Most of the rest are splice site mutations that
result in exon skipping, although some have more com-
plex outcomes and a smaller number are larger genomic
deletions [17]. There are no correlations between the
nature or location of the mutation and the type or
frequency of major complications [17].
The mutation c.1493G>A was detected in heterozy-
gosity in the COL3A1 gene, which resulted in a substitu-
tion of a Gly, a neutral amino acid, to aspartic acid, a
polar amino acid. The meta-analysis, conducted by
PolyPhen-2, SIFT, PROVEAN, and Align GVGD [12–15]
showed that this point mutation was pathogenetic and
a)                                                                      b)
SUBSTITUTION Gv Gd PREDICTION
G498D 0.00 93.77 Class C65
Fig. 3 Data analysis. PolyPhen-2 prediction indicated that a c.1493G>A (p.G498D) probably damages the structure of the protein (on the basis of
two different datasets Human Diversity and Human Variation). b Align GVGD indicated that c.1493G>A (p.G498D) is deleterious (class 65)
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was the cause of vEDS phenotype. The Gly substitution
negatively influences the normal assembly of COL3A1
collagen fibers. In fact, the collagen characteristic is
represented by the 343 repetitions of Gly-X-Y (X and Y,
any other amino acids) [16]. The Gly amino acid is very
important because it is the smallest amino acid and
determines the link between the three peptide chains.
The mutation c.1493G>A, p.G498D was located on the
triple helical region and it was theoretically conceivable
that this type of mutation may change the characteristic
triple helical structure and generate a severer phenotype.
In fact, substitution of Gly in this region of the protein
may strongly interfere with helix formation, delay the
triple helix assembly, and lead to a severe modification.
The negative effect was a dramatic decrease in the quan-
tity and quality of COL3A1 protein. We did not have an
opportunity to study the effect of this mutation on the
three-dimensional protein structure because, in the litera-
ture, there is no sequence homology.
Conclusions
We conclude that c.1493G>A, p.G498D identified in
COL3A1 gene was the cause of vEDS. The particular
position of Gly substitution suggested a correlation be-
tween genotype and phenotype. The functional properties
of c.1493G>A, p.G498D are still unknown, further studies
on in vitro cell culture will be necessary to understand the
link between this new variant and vEDS phenotype. The
discovery of this new variant in vEDS underlines the im-
portance of genetic tests as NGS in rare genetic diseases.
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